HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 62.3%

Neg 62.3% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.